Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ SIMPONI / SIMPONI ARIA — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Quanterix Corporation logo
QTRXSimoa — Total revenues
$6.68M-24.3%
Collegium Pharmaceutical, Inc. logo
COLLSymproic and other — Product revenues, net
$3.61M-4.3%
Organon logo
OGNSingulair — Revenue
$40M-45.9%
Collegium Pharmaceutical, Inc. logo
COLLSymproic — Product revenues, net
$4.19M+49.0%
Organon logo
OGNOther Biosimilars — Revenue
$24M+380%
Biogen logo
BIIBSPINRAZA — Total Revenue
$374M-11.8%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's simponi / simponi aria — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's SIMPONI / SIMPONI ARIA — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported SIMPONI / SIMPONI ARIA — sales to customers (note 9) of $647M in Q1 2026.
How has Johnson & Johnson's SIMPONI / SIMPONI ARIA — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's SIMPONI / SIMPONI ARIA — sales to customers (note 9) decreased by 1.8% year-over-year, from $659M to $647M.
What is the long-term trend for Johnson & Johnson's SIMPONI / SIMPONI ARIA — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's SIMPONI / SIMPONI ARIA — sales to customers (note 9) has grown at a 4.1% compound annual growth rate (CAGR), from $2.28B to $2.67B.
What does SIMPONI / SIMPONI ARIA — sales to customers (note 9) mean?
This metric represents the total net revenue generated from the sale of Simponi and Simponi Aria, which are biologic therapies used to treat various autoimmune and inflammatory conditions. It reflects the market demand and commercial performance of these specific pharmaceutical assets within the company's immunology portfolio. Tracking this revenue helps investors assess the product's lifecycle stage and its contribution to the company's overall therapeutic segment performance.